FDA Clears Johnson & Johnson Myeloma Combo, Expanding Frontline Care
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved a new frontline treatment option for adults newly diagnosed with multiple myeloma who …
FDA Clears Johnson & Johnson Myeloma Combo, Expanding Frontline Care Read More